Triplet Therapy in Metastatic Castrate Sensitive Prostate Cancer (mCSPC)—A Potential New Standard of Care
The treatment paradigm for metastatic castrate-sensitive prostate cancer (mCSPC) has evolved rapidly in the past decade with the approval of several life-prolonging therapies including docetaxel chemotherapy and multiple androgen receptor pathway inhibitors (ARPI) in combination with androgen depriv...
Збережено в:
| Автори: | , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
MDPI AG
2023-04-01
|
| Серія: | Current Oncology |
| Предмети: | |
| Онлайн доступ: | https://www.mdpi.com/1718-7729/30/4/332 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|